Log In
BCIQ
Print this Print this
 

Eldepryl, selegiline

  Manage Alerts
Collapse Summary General Information
Company Orion Corp.
DescriptionSelective monoamine oxidase B (MAO-B) inhibitor,
Molecular Target Monoamine oxidase B (MAO-B)
Mechanism of ActionMonoamine oxidase B (MAO-B) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat Parkinson's disease (PD)
Regulatory Designation
PartnerEisai Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/25/2011

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today